# Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque

Study · id `cardio:ct-nct07586540` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07586540](<https://clinicaltrials.gov/study/NCT07586540>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07586540

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 280 participants.

## Technical summary

Registry record NCT07586540. Randomized; triple masking; primary purpose treatment. Start 2026-01-06 (actual); primary completion 2030-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 280 participants (planned count; ClinicalTrials.gov record NCT07586540, source copy `cardio:ctgov-nct07586540-2026-11-12`, retrieved 2026-11-18)
- Started: 2026-01-06 (actual) (ClinicalTrials.gov record NCT07586540, source copy `cardio:ctgov-nct07586540-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2030-03 (anticipated) (ClinicalTrials.gov record NCT07586540, source copy `cardio:ctgov-nct07586540-2026-11-12`, retrieved 2026-11-18)
- Completion: 2030-09 (anticipated) (ClinicalTrials.gov record NCT07586540, source copy `cardio:ctgov-nct07586540-2026-11-12`, retrieved 2026-11-18)
- Countries: Egypt; Jordan; Morocco; Pakistan; Qatar; Saudi Arabia; Tunisia; Türkiye (ClinicalTrials.gov record NCT07586540, source copy `cardio:ctgov-nct07586540-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07586540-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque
- Acronym: CAROTID-STABIL
- Condition: Carotid Stenosis
- Intervention (Drug): Alirocumab
- Intervention (Drug): Placebo
- Intervention (Drug): Atorvastatin
- Lead sponsor: Middle East North Africa Stroke and Interventional Neurotherapies Organization
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Carotid artery stenosis (`cardio:carotid-stenosis`)
- Registry intervention name matches this record: Alirocumab (`cardio:alirocumab`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)

## Provenance

Content hash: cc5314ea7b90162c1c8d032c6cdadde6af2fd061727d5d7a3021e818bf2c5a6e
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
